Yevgeniya Kaykova, MD
Infectious Disease · New York, NYNPI 1376634915
Payments from drug & device makers
Across 721 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- Viiv Healthcare Company$2K
- AstraZeneca$2K
- AbbVie$2K
- Boehringer Ingelheim$1K
- Novo Nordisk$936
- plus $5K from 30 others
What the payments were for
- Food & beverage$15,96099%
- Education$1351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 120 | $2,771 |
| Viiv Healthcare Company | 91 | $2,320 |
| AstraZeneca | 109 | $2,297 |
| AbbVie(2 entities) | 94 | $1,855 |
| Boehringer Ingelheim | 48 | $1,378 |
| Novo Nordisk | 43 | $936 |
| Pfizer | 43 | $931 |
| Lilly USA, LLC | 38 | $710 |
| Merck | 34 | $667 |
| Johnson & Johnson(2 entities) | 13 | $281 |
| Insmed, Inc. | 11 | $270 |
| Amgen | 12 | $237 |
| Lundbeck LLC | 10 | $187 |
| Astellas Pharma US Inc | 8 | $185 |
| Amarin Pharma, Inc. | 4 | $153 |
| Nestle Healthcare Nutrition Inc. | 5 | $107 |
| Sumitomo Pharma America, Inc. | 5 | $93 |
| Alkermes, Inc. | 1 | $85 |
| Idorsia Pharmaceuticals US Inc | 4 | $84 |
| GSK | 3 | $75 |
| Theratechnologies Inc. | 3 | $73 |
| Paratek Pharmaceuticals, Inc. | 3 | $62 |
| Genentech USA, Inc. | 3 | $45 |
| Ironwood Pharmaceuticals, Inc | 2 | $41 |
| Napo Pharmaceuticals Inc | 2 | $37 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $22 |
| Exact Sciences | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Optinose US, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Mylan Institutional Inc. | 1 | $16 |
| Circassia Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,095 in reported general payments places this provider in the 80th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 16 | $67,842 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $57,561 |
| EliquisApixaban | 42 | $53,158 |
| DescovyEmtricitabine/Tenofov Alafenam | 20 | $44,891 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $41,129 |
| JardianceEmpagliflozin | 28 | $40,947 |
| MounjaroTirzepatide | 30 | $31,152 |
| OzempicSemaglutide | 33 | $30,692 |
| JanuviaSitagliptin Phosphate | 37 | $29,732 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $24,263 |
| FarxigaDapagliflozin Propanediol | 24 | $20,984 |
| XareltoRivaroxaban | 24 | $20,780 |
| MyrbetriqMirabegron | 27 | $15,575 |
| LyricaPregabalin | 11 | $11,375 |
| Hydrocortisone | 19 | $7,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $2,771 | $102,45235 claims |
| PfizerEliquis, Lyrica | $931 | $64,53453 claims |
| MerckJanuvia, Janumet | $667 | $53,99552 claims |
| Viiv Healthcare CompanyDovato | $2,320 | $41,12912 claims |
| Boehringer IngelheimJardiance | $1,378 | $40,94728 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $2,297 | $31,96448 claims |
| Lilly USA, LLCMounjaro | $710 | $31,15230 claims |
| Novo NordiskOzempic | $936 | $30,69233 claims |
| Johnson & JohnsonXarelto | $281 | $20,78024 claims |
| Astellas Pharma US IncMyrbetriq | $185 | $15,57527 claims |
| AbbVieLumigan, Synthroid | $1,855 | $7,20548 claims |
| GSKTrelegy Ellipta | $75 | $7,08312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 799 infectious disease providers in New York.
Other infectious disease in New York
- Wafaa El SadrNew York$119.1M
- Judith AbergNew York$14.8M
- Magdalena SobieszczykNew York$2.9M
- Kristen MarksNew York$2.8M
- Genovefa PapanicolaouNew York$2.7M
- Thomas WalshNew York$1.4M
- Sean LiuNew York$1.4M
- Martin MarkowitzNew York$1.4M
- Angelica KottkampNew York$1.2M
- Michelle CespedesNew York$819K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.